Merck KGaA, Pfizer Get Positive CHMP Opinion on Bavencio for Bladder Cancer
December 11 2020 - 8:59AM
Dow Jones News
By Cecilia Butini
Merck KGaA said Friday that the European Medicines Agency's
Committee for Medicinal Products for Human Use, or CHMP, has given
a positive opinion recommending approval of bladder-cancer
treatment Bavencio, which it developed in a partnership with Pfizer
Inc.
The German pharmaceuticals-and-chemicals company said that the
European Commission will review the agency's opinion and that a
decision is expected in early 2021.
The drug was given a recommendation for the first-line
maintenance treatment of adult patients with locally advanced or
metastatic urothelial carcinoma, or bladder cancer, Merck said.
Bavencio is an immunotherapy which was proven to prolong overall
survival in patients suffering from that type of cancer during a
phase 3 trial.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
December 11, 2020 08:44 ET (13:44 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck KGaA (PK) (USOTC:MKKGY)
Historical Stock Chart
From Apr 2023 to Apr 2024
